Table 3.

Gene expression analysis in PBMCs

A. Immune Gene Expression Over Time
	C1D8	C2D1	Average Expression	F	P value	Adjusted P value
IFI27	5.1	−0.89	7.65	20.56	< 0.00001	0.001
SIGLEC1	3.43	1.03	7.42	13.27	< 0.0001	0.025
CDK1	1.85	0.08	5.23	10.97	< 0.001	0.061
MX1	1.88	0.81	10.56	9.34	< 0.001	0.12
CD38	1.63	0.48	7.26	8.98	< 0.001	0.12
B. Relative Immune Gene Expression in Patients with CR/PR/SD vs. PD (NE excluded)
	C1D1	C1D8	C2D1		P value
CD1b	−1.66	-	-		0.03
IL17F	1.8	-	-		0.01
HLA-C	-	−2.06	-		0.04
MAPK14	-	−1.83	-		0.04
MAGEA4	-	1.55	-		0.05
CCL7	-	1.69	-		0.02
CD63	-	-	−2.13		0.03
LY96	-	-	−1.93		0.02
LTF	-	-	−1.89		0.02
TXK	-	-	−1.72		0.02
TNFSF13	-	-	−1.6		0.05
IL25	-	-	−1.59		0.03
C1QB	-	-	−1.51		0.04
CSF1	-	-	1.73		0.03
ICOS	-	-	2		0.04
LILRA4	-	-	2.1		0.02
TICAM2	-	-	2.28		0.03
C. Immune Gene Expression in long- vs. short-term survivors (cut-off 6 months)
	logFC	Average Expression	t	P value	Adjusted P value	B
HLA-DRB4	−5.02	6.22	−4.84	<0.001	0.023	2.22
TIGIT	0.94	7.49	4.086165	<0.001	0.1	0.38
TARP	1.23	8.72	3.817007	<0.001	0.13	−0.27
SPA17	−1.39	4.31	−3.74	<0.001	0.13	−0.46
CXCR5	1.09	5.9	3.62	0.001	0.13	−0.77
FCGR2A	−1.2	11.09	−3.56	0.001	0.13	−0.88
HLA-C	−0.99	12.39	−3.52	0.001	0.13	−0.96
KLRG1	1.36	8.19	3.5	0.001	0.13	−1
CD83	0.75	6.02	3.34	0.002	0.17	−1.38
CD3D	0.89	9.56	3.15	0.003	0.25	−1.81

CR=complete response, PD=progressive disease, PR=partial response, NE=non-evaluable, SD=stable disease